Jpmorgan Chase & CO Alvotech Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Alvotech stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,709 shares of ALVO stock, worth $21,738. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,709
Previous 4,368
60.87%
Holding current value
$21,738
Previous $53,000
62.26%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ALVO
# of Institutions
36Shares Held
15.6MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA3.17MShares$40.4 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$34.4 Million28.94% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca2.53MShares$32.2 Million0.64% of portfolio
-
Morgan Stanley New York, NY1.74MShares$22.1 Million0.0% of portfolio
-
Littlejohn & CO LLC1.32MShares$16.8 Million6.38% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $3.16B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...